Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 153

1.

Detection and characterization of murine colitis and carcinogenesis by molecularly targeted contrast-enhanced ultrasound.

Brückner M, Heidemann J, Nowacki TM, Cordes F, Stypmann J, Lenz P, Gohar F, Lügering A, Bettenworth D.

World J Gastroenterol. 2017 Apr 28;23(16):2899-2911. doi: 10.3748/wjg.v23.i16.2899.

2.

FGF23/FGFR4-mediated left ventricular hypertrophy is reversible.

Grabner A, Schramm K, Silswal N, Hendrix M, Yanucil C, Czaya B, Singh S, Wolf M, Hermann S, Stypmann J, Di Marco GS, Brand M, Wacker MJ, Faul C.

Sci Rep. 2017 May 16;7(1):1993. doi: 10.1038/s41598-017-02068-6.

3.

De novo hereditary (familial) amyloid polyneuropathy (FAP) in a FAP liver recipient.

Guttmann S, Röcken C, Schmidt M, Grünewald I, Zibert A, Stypmann J, Schilling M, Schmidt H.

Amyloid. 2017 Mar;24(sup1):126-127. doi: 10.1080/13506129.2017.1293642. No abstract available.

PMID:
28434329
4.

Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease.

Lenders M, Schmitz B, Stypmann J, Duning T, Brand SM, Kurschat C, Brand E.

Nephrol Dial Transplant. 2016 Sep 27. pii: gfw334. [Epub ahead of print]

PMID:
27679524
5.

Physical Exercise in Patients with Fabry Disease - a Pilot Study.

Schmitz B, Thorwesten L, Lenders M, Duning T, Stypmann J, Brand E, Brand SM.

Int J Sports Med. 2016 Dec;37(13):1066-1072. Epub 2016 Sep 27.

PMID:
27676143
6.

Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease.

Lenders M, Hennermann JB, Kurschat C, Rolfs A, Canaan-Kühl S, Sommer C, Üçeyler N, Kampmann C, Karabul N, Giese AK, Duning T, Stypmann J, Krämer J, Weidemann F, Brand SM, Wanner C, Brand E.

Orphanet J Rare Dis. 2016 Jun 29;11(1):88. doi: 10.1186/s13023-016-0473-4.

7.

Sphingosine-1-Phosphate Receptor 1 Regulates Cardiac Function by Modulating Ca2+ Sensitivity and Na+/H+ Exchange and Mediates Protection by Ischemic Preconditioning.

Keul P, van Borren MM, Ghanem A, Müller FU, Baartscheer A, Verkerk AO, Stümpel F, Schulte JS, Hamdani N, Linke WA, van Loenen P, Matus M, Schmitz W, Stypmann J, Tiemann K, Ravesloot JH, Alewijnse AE, Hermann S, Spijkers LJ, Hiller KH, Herr D, Heusch G, Schäfers M, Peters SL, Chun J, Levkau B.

J Am Heart Assoc. 2016 May 20;5(5). pii: e003393. doi: 10.1161/JAHA.116.003393.

8.

Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant.

Lenders M, Weidemann F, Kurschat C, Canaan-Kühl S, Duning T, Stypmann J, Schmitz B, Reiermann S, Krämer J, Blaschke D, Wanner C, Brand SM, Brand E.

Orphanet J Rare Dis. 2016 May 4;11(1):54. doi: 10.1186/s13023-016-0441-z.

9.

Imaging Reveals the Connection Between Spontaneous Coronary Plaque Ruptures, Atherothrombosis, and Myocardial Infarctions in HypoE/SRBI-/- Mice.

Hermann S, Kuhlmann MT, Starsichova A, Eligehausen S, Schäfers K, Stypmann J, Tiemann K, Levkau B, Schäfers M.

J Nucl Med. 2016 Sep;57(9):1420-7. doi: 10.2967/jnumed.115.171132. Epub 2016 Apr 28.

PMID:
27127225
10.

The Synthetic Tie2 Agonist Peptide Vasculotide Protects Renal Vascular Barrier Function In Experimental Acute Kidney Injury.

Rübig E, Stypmann J, Van Slyke P, Dumont DJ, Spieker T, Buscher K, Reuter S, Goerge T, Pavenstädt H, Kümpers P.

Sci Rep. 2016 Feb 25;6:22111. doi: 10.1038/srep22111.

11.

Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II.

Crespo-Leiro MG, Stypmann J, Schulz U, Zuckermann A, Mohacsi P, Bara C, Ross H, Parameshwar J, Zakliczyński M, Fiocchi R, Hoefer D, Colvin M, Deng MC, Leprince P, Elashoff B, Yee JP, Vanhaecke J.

Eur Heart J. 2016 Sep 1;37(33):2591-601. doi: 10.1093/eurheartj/ehv682. Epub 2016 Jan 7.

12.

Renal Contrast-Enhanced Sonography Findings in a Model of Acute Cellular Allograft Rejection.

Grabner A, Kentrup D, Pawelski H, Mühlmeister M, Biermann C, Edemir B, Heitplatz B, Van Marck V, Bettinger T, Pavenstädt H, Schlatter E, Stypmann J, Tiemann K, Reuter S.

Am J Transplant. 2016 May;16(5):1612-9. doi: 10.1111/ajt.13648. Epub 2016 Feb 26.

13.

Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.

Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E, Samano ET, Müller K, Roessig L, Pieske B; SOCRATES-REDUCED Investigators and Coordinators.

JAMA. 2015 Dec 1;314(21):2251-62. doi: 10.1001/jama.2015.15734.

PMID:
26547357
14.

Performance of gene-expression profiling test score variability to predict future clinical events in heart transplant recipients.

Crespo-Leiro MG, Stypmann J, Schulz U, Zuckermann A, Mohacsi P, Bara C, Ross H, Parameshwar J, Zakliczyński M, Fiocchi R, Hoefer D, Deng M, Leprince P, Hiller D, Eubank L, Deljkich E, Yee JP, Vanhaecke J.

BMC Cardiovasc Disord. 2015 Oct 9;15:120. doi: 10.1186/s12872-015-0106-1.

15.

Inhomogeneous myocardial stress perfusion in SPECT studies predicts future allograft dysfunction in heart transplant recipients.

Wenning C, Vrachimis A, Dell Aquila A, Penning A, Stypmann J, Schäfers M.

EJNMMI Res. 2015 Dec;5(1):51. doi: 10.1186/s13550-015-0129-8. Epub 2015 Oct 5.

16.

Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.

Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, Martin A, Fornoni A, Di Marco GS, Kentrup D, Reuter S, Mayer AB, Pavenstädt H, Stypmann J, Kuhn C, Hille S, Frey N, Leifheit-Nestler M, Richter B, Haffner D, Abraham R, Bange J, Sperl B, Ullrich A, Brand M, Wolf M, Faul C.

Cell Metab. 2015 Dec 1;22(6):1020-32. doi: 10.1016/j.cmet.2015.09.002. Epub 2015 Oct 1.

17.

The MANDELA study: A multicenter, randomized, open-label, parallel group trial to refine the use of everolimus after heart transplantation.

Deuse T, Bara C, Barten MJ, Hirt SW, Doesch AO, Knosalla C, Grinninger C, Stypmann J, Garbade J, Wimmer P, May C, Porstner M, Schulz U.

Contemp Clin Trials. 2015 Nov;45(Pt B):356-63. doi: 10.1016/j.cct.2015.09.009. Epub 2015 Sep 9.

PMID:
26363128
18.

Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.

Lenders M, Canaan-Kühl S, Krämer J, Duning T, Reiermann S, Sommer C, Stypmann J, Blaschke D, Üçeyler N, Hense HW, Brand SM, Wanner C, Weidemann F, Brand E.

J Am Soc Nephrol. 2016 Mar;27(3):952-62. doi: 10.1681/ASN.2015030337. Epub 2015 Jul 16.

19.

Cardiac involvement in female Duchenne and Becker muscular dystrophy carriers in comparison to their first-degree male relatives: a comparative cardiovascular magnetic resonance study.

Florian A, Rösch S, Bietenbeck M, Engelen M, Stypmann J, Waltenberger J, Sechtem U, Yilmaz A.

Eur Heart J Cardiovasc Imaging. 2016 Mar;17(3):326-33. doi: 10.1093/ehjci/jev161. Epub 2015 Jun 25.

PMID:
26113120
20.

Low-Energy Ultrasound Treatment Improves Regional Tumor Vessel Infarction by Retargeted Tissue Factor.

Brand C, Dencks S, Schmitz G, Mühlmeister M, Stypmann J, Ross R, Hintelmann H, Schliemann C, Müller-Tidow C, Mesters RM, Berdel WE, Schwöppe C.

J Ultrasound Med. 2015 Jul;34(7):1227-36. doi: 10.7863/ultra.34.7.1227.

PMID:
26112625

Supplemental Content

Loading ...
Support Center